沙库巴曲缬沙坦剂量与HFrEF患者预后生物标志物、健康状况及心脏重构的剂量-反应关系
本研究纳入794例射血分数≤40%的心衰患者,按沙库巴曲缬沙坦平均日剂量三分位分组,评估12个月内生物标志物、健康状况及心脏重构变化。结果显示不同剂量组在预后生物标志物改善、KCCQ-23评分提升及心脏逆重构方面均相似。
要点
- 低、中、高剂量沙库巴曲缬沙坦组在12个月内的预后生物标志物改善程度相似。
- 不同剂量组的KCCQ-23评分提升和心脏逆重构指标改善均相当。
- 临床实践中沙库巴曲缬沙坦剂量差异未显著影响上述结局的改善幅度。
核心结论
- 在HFrEF患者中,不同沙库巴曲缬沙坦剂量组在预后生物标志物、健康状况和心脏重构方面观察到相似的改善。
研究设计与样本
- 研究纳入794例HFrEF患者(射血分数≤40%),按沙库巴曲缬沙坦平均日剂量三分位分组,评估12个月治疗期间的变化。
主要发现
- 低、中、高剂量组平均日剂量分别为112 mg、342 mg和379 mg。
- 所有剂量组的预后生物标志物变化相似。
- KCCQ-23评分提升在各剂量组相当。
- 低、中、高剂量组左心室射血分数中位绝对改善分别为9.3%、8.7%和10.2%,左房和左室容积及E/e'改善也相似。
临床怎么用
- 临床实践中可依据患者耐受性调整沙库巴曲缬沙坦剂量,不同剂量均可能带来相似的生物标志物、健康状况和心脏重构改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure with reduced ejection fraction (HFrEF) are often not reached in clinical practice. OBJECTIVES: The purpose of this study was to investigate associations among Sac/Val doses and changes in prognostic biomarkers, health status, and cardiac remodeling among individuals with HFrEF through 12 months of treatment with Sac/Val administered per usual care. METHODS: A total of 794 persons with HFrEF (ejection fraction [EF] ≤40%) were categorized according to average daily doses of Sac/Val divided into tertiles. Change from baseline to 12 months in biomarkers (N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, soluble ST2, atrial natriuretic peptide, urinary cyclic guanosine monophosphate), Kansas City Cardiomyopathy Questionnaire-23 scores, and parameters of cardiac reverse remodeling (left ventricular EF, indexed left atrial and ventricular volumes, and E/e') were assessed. RESULTS: The average daily dose was 112 mg in Tertile 1 (low dose), 342 mg in Tertile 2 (moderate dose), and 379 mg in Tertile 3 (high dose). Similar changes in prognostic biomarkers were observed in all dose tertiles. Gains in Kansas City Cardiomyopathy Questionnaire-23 scores were comparable regardless of dose category. Consistent reverse cardiac remodeling in all dose categories occurred; the median absolute left ventricular EF improvement across HF dose groups was 9.3%, 8.7%, and 10.2%, for low, moderate, and high doses, respectively; similar improvements in left atrial and ventricular volumes and E/e' were also observed across dose categories. CONCLUSIONS: Among patients with HFrEF, similar improvement in prognostic biomarkers, health status, and cardiac remodeling were observed across various Sac/Val doses. (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183.
引用
- Mohebi, Liu, Piña, et al. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36229089. doi:10.1016/j.jacc.2022.08.737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。